ResearcherJilin UniversityActive in the last 2 years

Hongqiao Cai

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5060310533. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

EGFR-antibody-decorated cancer-cell-membrane-coated MOF nanoplatform enables targeted delivery of the STING agonist diABZI for pancreatic cancer immunotherapy. Last author DOI 10.1016/j.ijpx.2026.100678 ↗
Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy. Co-author DOI 10.1021/acs.molpharmaceut.0c01225 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Qingmin Chen · 1 shared paper, 2026 · strength 0.39
- Paper EGFR-antibody-decorated cancer-cell-membrane-coated MOF nanoplatform enables targeted delivery of the STING agonist diA… DOI 10.1016/j.ijpx.2026.100678 ↗
Ruobing Wang · 1 shared paper, 2021 · strength 0.15
- Paper Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy. DOI 10.1021/acs.molpharmaceut.0c01225 ↗
Xingren Guo · 1 shared paper, 2021 · strength 0.15
- Paper Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy. DOI 10.1021/acs.molpharmaceut.0c01225 ↗
Yahui Liu · 1 shared paper, 2021 · strength 0.15
- Paper Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy. DOI 10.1021/acs.molpharmaceut.0c01225 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.